ADCETRIS (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
ADCETRIS
Date registered
Evaluation commenced
Decision date
Approval time
219 (255 working days)
Active ingredients
Brentuximab vedotin
Registration type
EOI
Indication
Treatment of adult patients with previously untreated CD30+ Stage IIB with large mediastinal mass and/or extranodal disease, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD).